Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. 2007

Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
Department of Therapeutic Radiology and Oncology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. mitsumo@kuhp.kyoto-u.ac.jp

BACKGROUND An International Atomic Energy Agency (IAEA)-sponsored, multi-institutional prospective randomized trial was conducted to clarify whether the combination of hyperthermia and radiotherapy improves the local response rate of locally advanced non-small cell lung cancer (NSCLC) compared with that obtained by radiotherapy alone. METHODS Between October 1998 and April 2002, 80 patients with locally advanced NSCLC were randomized to receive either standard radiation therapy alone (RT) or radiation therapy combined with hyperthermia (RT + HT). The primary endpoint was the local response rate. The secondary endpoints were local progression-free survival and overall survival. RESULTS The median follow-up period was 204 days for all patients and 450 days for surviving patients. There were no significant differences between the two arms with regard to local response rate (P = 0.49) or overall survival rate (P = 0.868). However, local progression-free survival was significantly better in the RT+HT arm (P = 0.036). Toxicity was generally mild and no grade 3 late toxicity was observed in either arm. CONCLUSIONS Although improvement of local progression-free survival was observed in the RT+HT arm, this prospective randomized study failed to show any substantial benefit from the addition of hyperthermia to radiotherapy in the treatment of locally advanced NSCLC.

UI MeSH Term Description Entries
D007036 Hypothermia, Induced Abnormally low BODY TEMPERATURE that is intentionally induced in warm-blooded animals by artificial means. In humans, mild or moderate hypothermia has been used to reduce tissue damages, particularly after cardiac or spinal cord injuries and during subsequent surgeries. Induced Hypothermia,Mild Hypothermia, Induced,Moderate Hypothermia, Induced,Targeted Temperature Management,Therapeutic Hypothermia,Hypothermia, Therapeutic,Induced Mild Hypothermia,Induced Mild Hypothermias,Induced Moderate Hypothermia,Induced Moderate Hypothermias,Mild Hypothermias, Induced,Moderate Hypothermias, Induced,Targeted Temperature Managements
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
January 2005, International journal of radiation oncology, biology, physics,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
July 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
July 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
June 2022, International journal of clinical oncology,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
June 2002, American journal of clinical oncology,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
September 2009, European journal of cancer (Oxford, England : 1990),
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
March 2014, Radiation oncology (London, England),
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
January 1992, International journal of radiation oncology, biology, physics,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
February 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Michihide Mitsumori, and Zhi-Fan Zeng, and Praskovya Oliynychenko, and Jeong Ho Park, and Ihl Bohng Choi, and Hideo Tatsuzaki, and Yoshiaki Tanaka, and Masahiro Hiraoka
January 2022, Advances in radiation oncology,
Copied contents to your clipboard!